Results 1 to 10 of about 414,143 (313)

Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan

International Journal for Equity in Health, 2019
Background Out-of-pocket (OOP) payments can constitute a major barrier for affordable and equitable access to essential medicines. Household surveys in Kyrgyzstan pointed to a perceived growth in OOP payments for outpatient medicines, including those ...
Sabine Vogler, Peter Schneider, Guillaume Dedet, Hanne Bak Pedersen   +3 more
doaj   +1 more source

Pricing of orphan drugs in oncology and rare diseases

Journal of Market Access & Health Policy, 2020
Objective: The objective of this paper is to determine an upper price limit for an orphan drug by taken a broader perspective and, including also other monetary and non-monetary values for the society.
Mark Nuijten, Stefano Capri
doaj   +1 more source

Medicare Reimbursement for Total Joint Arthroplasty: The Driving Forces. [PDF]

, 2016
BACKGROUND: Total joint arthroplasty is a large and growing part of the U.S. Medicare budget, drawing attention to how much providers are paid for their services. The purpose of this study was to examine the variables that affect total joint arthroplasty
Howley, Michael, Padegimas, Eric M., Purtill, James J., Rothman, Richard H., Verma, Kushagra, Zmistowski, Benjamin   +5 more
core   +1 more source

Examining confidential wholesale margin estimates in European countries for the price negotiation of patented drugs in Germany: a statistical model

Health Economics Review
Background Based on the legal framework laid down in section 130b (9) of Book V of the German Social Code, various criteria are relevant for the negotiated price for new patented drugs in Germany. European reference prices (ERPs) are one criterion.
Iris an der Heiden, Guido Schiffhorst, Laura Müller, Martin Albrecht, Arne Bartol, Stefanie Wiberny   +5 more
doaj   +1 more source

Understanding the adoption of new drugs decided by several stakeholders in the South Korean market: a nonparametric event history analysis

Health Economics Review, 2018
Background Regulatory approval and reimbursement decisions are necessary if new drugs are to become accessible in a timely manner. However, the process of regulatory approval and the establishment of reimbursement decisions varies across countries.
Kyung-Bok Son
doaj   +1 more source

Affordability of oncology drugs: accuracy of budget impact estimations

Journal of Market Access & Health Policy, 2020
Background: In many countries, Budget Impact (BI) informs reimbursement decisions. Evidence has shown that decision-makers have restricted access based on high BI estimates but studies show that BI estimates are often inaccurate. Objective: To assess the
Joost W. Geenen, Mark Jut, Cornelis Boersma, Olaf H. Klungel, Anke M. Hövels   +4 more
doaj   +1 more source

Examining the association between oncology drug clinical benefit and the time to public reimbursement

Cancer Medicine, 2022
Background We examined if oncology drug indications with high clinical benefit, as measured by the American Society of Clinical Oncology Value Framework (ASCO‐VF) and European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO‐MCBS ...
Sasha Thomson, Louis Everest, Noah Witzke, Tina Jiao, Seanthel Delos Santos, Vivian Nguyen, Matthew C. Cheung, Kelvin K. W. Chan   +7 more
doaj   +1 more source

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia

Frontiers in Pharmacology, 2021
Background: The aim of this study was to investigate the impact of selected legislative initiatives and their implementation for off-patent medicinal products in Slovakia compared with the rest of the Visegrád Group (V4 countries).Methods: We analyzed ...
Tomas Tesar, Peter Golias, Lucia Masarykova, Paweł Kawalec, András Inotai, András Inotai   +5 more
doaj   +1 more source

Innovative Payment Mechanisms for High-Cost Medical Devices in Latin America: Experience in Designing Outcome Protection Programs in the Region

Journal of Market Access & Health Policy
Introduction and Objectives: Risk-sharing agreements (RSAs) have emerged as a key strategy for financing high-cost medical technologies while ensuring financial sustainability.
Daniela Paredes-Fernández, Juan Valencia-Zapata   +1 more
doaj   +1 more source

Technological adoption in health care [PDF]

This paper addresses the impact of payment systems on the rate of technology adoption. We present a model where technological shift is driven by demand uncertainty, increased patients' benefit, financial variables, and the reimbursement system to ...
Pedro Pita Barros, Xavier Martinez-Giralt   +1 more
core   +3 more sources